TPTX » Topics » Neuron.

This excerpt taken from the TPTX 8-K filed Jun 8, 2006.
Neuron. In this study, it was shown in mice that NGX267 lowered brain levels of A(-42 and could prevent the formation of both the amyloid plaque and neurofibillary tangles that are the pathological hallmarks of Alzheimer’s Disease. The authors concluded that NGX267 could potentially have important effects in delaying or preventing the progression of Alzheimer’s Disease.


Both companies have some very promising pre-clinical candidates that are highlighted here.


As Gosse previously mentioned, BNC is a highly selective butyrylcholinesterase inhibitor in late stage pre-IND development for the treatment of severe Alzheimer’s Disease.


NGX292, our follow-up muscarinic agonist and NGX555 are two additional IND candidates that are being targeted for the treatment of Alzheimer’s Disease.


NGX555, our gamma/secretase modulator, is a particularly significant compound as it comes directly from the discovery function of TorreyPines, and we believe validates the scientific excellence of the group.

These compounds, along with BNC, represent an important part of the future of the company.


Together with NGX267, Phenserine and Posiphen, these six compounds give the combined company, in my opinion, one of the strongest and most diversified pipelines for Alzheimer’s Disease in the pharmaceutical industry.

Before we close, I want to review the company’s anticipated clinical milestones during the next 12-months.


In Migraine and Chronic Pain, Tezampanel is expected to enter into a Phase IIb trial for treatment of migraine and we plan to file an IND for NGX426 and start a Phase I trial with the drug.



In our Alzheimer’s Disease Franchise, the ongoing Phase I trials with Posiphen for Alzheimer’s Disease progression should be completed, and data from the Phase I single dose study of NGX267 in healthy elderly should become available. We plan to begin a multiple dose Phase I trial with NGX267, and we plan to start a Phase I trial with BNC.


At this point, let me turn things over again to Gosse who will take you through the remainder of the presentation


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki